First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
Background The IMpower150 trial found that adding atezolizumab to the combination of bevacizumab and chemotherapy improved survival for patients with metastatic, nonsquamous non–small cell lung cancer (NSCLC). However, considering the high cost of immunotherapy, there is a need to assess its value b...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
2019
|
| Mynediad Ar-lein: | https://doi.org/10.1002/cncr.32368 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.32368 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|